Clinical Trials Logo
  1. Home
  2. Graves Disease
  3. NCT06068179

Graves' Disease Remission Study: MycoMeth Combo — 3M-RGD  

Graves' Disease Clinical Trial

Official title:
The Efficacy and Safety of Combining Mycophenolate Mofetil With Methimazole on Remission of Newly Diagnosis Graves' Disease (3M-RGD Trial): an Open-label, Randomized Trial

Clinical Trial Summary

A randomized study to evaluate the efficacy and safety of combining mycophenolate mofetil with methimazole in patients with newly diagnosed Graves' disease.

Clinical Trial Description

The remission rate of methimazole standard therapy in patients with newly diagnosed Graves' disease is only around 50%. Main reason for the low remission rate is methimazole therapy is not a drug targeting etiology of Graves' disease. The investigators hypothesize that adding mycophenolate mofetil, an immunosuppressor, to methimazole standard therapy will improve remission rate. The study will evaluate the efficacy and safety of combining mycophenolate mofetil with methimazole in patients with newly diagnosed Graves' disease. 205 eligible patients will be randomized to mycophenolate mofetil combined with methimazole therapy or methimazole standard therapy. The primary outcome is the remission rate at 12 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06068179
Study type Interventional
Source The First Affiliated Hospital of Xiamen University
Contact Fangsen Xiao, MD
Phone +8613859955389
Email xfs888@163.com
Status Recruiting
Phase Phase 2/Phase 3
Start date October 16, 2023
Completion date October 8, 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT01950260 - Early Levothyroxine Post Radioactive Iodine Phase 2/Phase 3
Completed NCT01269749 - Radioactive Iodide Therapy for Pediatric Graves' Disease Phase 2
Recruiting NCT02114619 - Comparative Study of Different I-131 Doses in Graves' Disease N/A
Completed NCT04383795 - Change of Gut Microbiome in the Treatment of Graves' Disease
Completed NCT02384668 - D-vitamin And Graves' Disease; Morbidity And Relapse Reduction N/A
Completed NCT01885533 - Post-Radioiodine Graves' Management: The PRAGMA-Study N/A
Completed NCT01534169 - Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients Phase 1
Completed NCT00917241 - Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone Phase 4
Completed NCT00004660 - Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy N/A
Completed NCT02205801 - Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy N/A
Recruiting NCT02620085 - Thyroid Disease and Personality Study N/A
Completed NCT00958113 - Autoimmune Thyroid Disease Genetic Study N/A
Completed NCT02727738 - Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole N/A
Completed NCT00697528 - Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy N/A
Completed NCT00150124 - Block-replacement Therapy During Radioiodine Therapy Phase 4
Completed NCT03535090 - Coagulation After Intravenous Methylprednisolone Administration
Not yet recruiting NCT02373995 - Role of the Microbiome in Graves' Orbitopathy Phase 1/Phase 2
Completed NCT00505011 - Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves’ Disease N/A
Completed NCT02107794 - Shared Decision Making in Graves Disease - Graves Disease (GD) Choice N/A
Recruiting NCT01182584 - Application of Digital Infrared Thermal Imaging (DITI) in Graves' Disease N/A